The Alliance of Angels Innovation Fund
Investing Together in the Next Generation of Innovation
The Alliance of Angels Innovation Fund is a member-led investment program backing high-potential companies across the Pacific Northwest and beyond.
The Alliance of Angels Innovation Fund is a member-led investment program backing high-potential companies across the Pacific Northwest and beyond.
About Us
About the Fund
The AoA Innovation Fund program raises a new fund each year for its members. Historically the funds have invested in 12-15 companies each, providing members with diversified exposure to early-stage innovation.
Investment
Deal Flow and Investment Focus
We leverage the established Alliance of Angels screening process, reviewing hundreds of deals each year.
While most investments come through AoA, the fund may also invest in companies outside the standard AoA process.
.svg)
Geographic Focus
Primarily Pacific Northwest companies (~70%), with openness to strong opportunities across the U.S. and Canada.
.svg)
Sector Focus
Sector agnostic — investments are driven by the strength of the deal and founding team.
One Member. One Vote.
This is a member-led fund, where all investment decisions are determined by member vote.
Identification
Voting
Investment
Members identify prospective companies, conduct group due diligence and write an investment recommendation.
Recommended companies are presented to the fund members – approval requires 75% Yes vs. No, with a 50% quorum.
When we invest we stay in contact with the company and help them syndicate their round with other investors.
Historically, the Innovation Funds have operated with exceptionally low expenses (<0.7%) due to its volunteer administrative team, and the fact that we rely on our members to participate in due diligence.
Who the Fund Is For
Built for New and Experienced Angels
The Alliance of Angels is committed to enhancing the startup ecosystem in the Pacific Northwest
The Alliance of Angels provides a training for first time entrepreneurs and people new to angel investing.
Participating in the Fund provides hands on investing experience
Innovation Fund Portfolio
Search Less. Discover More
3DBioFibR manufactures biopolymer fibers for medical, defense, and textile applications using patented dry-spinning tech.
Abacus develops therapeutic vaccines to treat cancer and chronic viral infections that cause cancer.
GenAI platform for simplifying software maintenance and modernization, generating modern enterprise-grade architecture, tech stack, and infrastructure as code.
Operator of a material science company producing renewable, biodegradable plastics from algae for applications like footwear and surfboards.
Ampd is the fastest, simplest, and most powerful way to launch and maximize Google Ads to marketplaces such as Amazon or Walmart.
Anuncia develops CSF Management/Neurocritical Care therapeutic & monitoring devices for noninvasive at-home use.
Aurenar is improving stroke outcomes and reducing hospital stays/costs with an easy-to-use non-invasive ear stimulation device that activates the body's naturally healing vagal nerve response--with validated clinical results from a recent randomized controlled clinical study.
Hardware security company building semiconductor inspection technology for high-reliability electronic component authentication and supply chain assurance.
CorRen is eliminating preventable amputations by bringing reimbursed, specialist-grade PAD testing to primary care.
%20(1).svg)
%20(1).svg)
Cyrus Biotechnology is a pre-clinical-stage AI-driven therapeutics company with an internal pipeline of novel biologics primarily in autoimmune indications.
.svg)
Cytogenetics platform that eliminates the need for multiple cytogenetic tests with a single comprehensive assay, combining genome-wide structural variation detection with molecular-level resolution.
AI-powered deposition intelligence for law firms — helps lawyers prepare for, run, and review depositions with deposition-focused AI.
Ecellix has developed silicon anodes that empower battery makers to shatter limits: high energy, low cost & long life.
Enosemi's semiconductor designs will power the next generation of photonic products for connectivity, computing, sensing, mixed reality, medtech, biotech, and beyond. Note: Enosemi had a successful exit in mid 2025, producing a return for both IF2 and IF4.
Our vision is to build an environment of technology to serve the airport of the future with the goal of increasing safety, efficiency, and to capture service revenue on 100M+ movements at airports each year.